A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)

Trial Profile

A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Lusutrombopag (Primary)
  • Indications Thrombocytopenia
  • Focus Registrational; Therapeutic Use
  • Acronyms L-PLUS 2
  • Sponsors Shionogi
  • Most Recent Events

    • 20 Oct 2017 Results presented in a Shionogi Media Release.
    • 20 Oct 2017 According to a Shionogi media release, data will be presented at the 25th United European Gastroenterology Week in Spain later this month, and at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in December.
    • 25 Sep 2017 According to a Shionogi media release, based on the results from the L-PLUS1 and L-PLUS2 Phase 3 studies, Shionogi has initiated rolling submission of a New Drug Application to the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top